⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

March 2, 2026Clinical Cancer ResearchOpen Access

Efficacy and Safety of Belantamab Mafodotin with Bortezomib Plus Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma: the DREAMM-6 Arm B Trial

Rakesh Popat Bradley Augustson Paul Cannell Keith Stockerl-Goldstein Andrew Spencer Amit Khot Ajay Nooka N. Patel Ravi S. Kasinathan Astrid McKeown Amy Curry Rachel Rogers Mehreen Shaikh Fernando Carreno Sumita Roy-Ghanta J. Opalinska Hang Quach

View Full Paper

Ask AI

Bookmark

Share

Key Points

To evaluate the efficacy and safety of Belantamab Mafodotin combined with Bortezomib and Dexamethasone in patients with relapsed/refractory multiple myeloma.
Conducted the DREAMM-6 Arm B trial
Administered Belantamab Mafodotin with Bortezomib plus Dexamethasone to heavily pretreated patients
Analyzed safety and efficacy across all dosing cohorts
Demonstrated manageable safety across all dosing cohorts
Showed clinical activity supporting the 2.5 mg/kg dose Q3W

Implication

This trial demonstrates manageable safety and clinical activity in relapsed/refractory multiple myeloma, suggesting a viable treatment option.

Abstract

BVd demonstrated manageable safety and clinical activity across all dosing cohorts in heavily pretreated RRMM, supporting the 2.5 mg/kg Q3W dose.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Popat et al. (2026) studied this question.

synapsesocial.com/papers/69a7cc8ed48f933b5eed8358 https://doi.org/10.1158/1078-0432.ccr-25-3216

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Exposure-response analyses for belantamab mafodotin in combination with bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma from DREAMM-6 Arm B and DREAMM-7Late-Phase Clinical Trial · 2026
2Final analysis results from DREAMM-3, a phase 3 study of belantamab mafodotin versus pomalidomide plus dexamethasone in patients with relapsed/refractory multiple myelomaLate-Phase Clinical Trial · 2026
3Belantamab mafodotin, bortezomib, and dexamethasone for RRMM in the Japan expansion cohort of the phase 3 DREAMM-7 trialCohort Study · 2026
4Exposure-response and dose simulation of belantamab mafodotin in combination with standards of care in patients with relapsed/refractory multiple myelomaLate-Phase Clinical Trial · 2026
5DREAMM-9 final analysis: Belantamab mafodotin (belamaf), bortezomib, lenalidomide, and dexamethasone (BVRd) for transplant-ineligible (TI) newly diagnosed multiple myeloma (NDMM).Early-Phase Clinical Trial · 2026 · 1 citations

More related papers

Results from the randomized phase 3 DREAMM-8 study of belantamab mafodotin plus pomalidomide and dexamethasone (BPd) vs pomalidomide plus bortezomib and dexamethasone (PVd) in relapsed/refractory multiple myeloma (RRMM).2024
Belantamab Mafodotin, Bortezomib, and Dexamethasone for Multiple Myeloma2024
Patient-reported outcomes (PROs) from the DREAMM-7 randomized phase 3 study comparing belantamab mafodotin, bortezomib, and dexamethasone (BVd) vs daratumumab, bortezomib, and dexamethasone (DVd) in patients with relapsed/refractory multiple myeloma (RRMM).2024

More from Clinical Cancer Research

Serial circulating tumour DNA monitoring in first-line advanced NSCLC (COPE): a randomized, two-arm non-comparative phase II trialWed,
DuoBody®-FAPαxDR4 is a novel DR4 agonist that induces potent antitumor activity through FAPα-dependent, DR4-transactivation-mediated apoptosisWed,